Biomea Fusion (BMEA) Projected to Post Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) is expected to be posting its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Biomea Fusion to post earnings of ($1.00) per share for the quarter.

Biomea Fusion Stock Performance

Shares of NASDAQ:BMEA opened at $2.87 on Friday. The company has a 50-day simple moving average of $3.47 and a 200-day simple moving average of $6.18. Biomea Fusion has a one year low of $2.35 and a one year high of $16.97. The stock has a market capitalization of $104.01 million, a price-to-earnings ratio of -0.72 and a beta of -0.26.

Wall Street Analyst Weigh In

BMEA has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Biomea Fusion in a report on Tuesday, January 14th. D. Boral Capital reissued a “buy” rating and set a $16.00 price target on shares of Biomea Fusion in a report on Wednesday. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Biomea Fusion presently has a consensus rating of “Buy” and an average price target of $29.18.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.